Aktis Oncology is a biotechnology company pioneering the discovery and development of a new class of targeted radiopharmaceuticals for solid tumor cancers.
Employees: 11-50
Total raised: $331M
Founded date: 2020
Investors 9
Funding Rounds 3
| Date | Series | Amount | Investors |
| 01.10.2024 | Series B | $175M | - |
| 26.08.2022 | Series A | $84M | - |
| 22.03.2021 | Series A | $72M | - |
Mentions in press and media 20
| Date | Title | Description |
| 28.05.2025 | Aktis Oncology Initiates Phase 1b Clinical Trial Of Its Nectin-4- Targeting Radiopharmaceutical Product Candidate, Aky-1189, Across Multiple Tumor Types | - |
| 01.10.2024 | Aktis Oncology: $175 Million (Series B) Secured To Develop Targeted Alpha Radiopharmaceuticals For Treating Tumors | Aktis Oncology, a clinical-stage biotechnology company pioneering the discovery and development of novel targeted alpha radiopharmaceuticals to treat a broad range of solid tumors, announced the successful closing of an oversubscribed and u... |
| 30.09.2024 | Radiopharma biotech Aktis sees Big Pharma backers return for $175M series B | Having banked $60 million from Eli Lilly in the spring, Aktis Oncology has now closed an upsized $175 million series B that saw the U.S. Big Pharma rejoin a range of big-name investors in the radiopharma biotech. Lilly was one of a number o... |
| 30.09.2024 | Aktis Oncology Raises $175M in Series B Funding | Aktis Oncology, a Boston, MA-based clinical-stage biotechnology company pioneering the discovery and development of novel targeted alpha radiopharmaceuticals to treat a broad range of solid tumors, closed a $175m Series B financing. The rou... |
| 13.06.2024 | Aktis Oncology Expands its Board of Directors with Appointment of Nuclear Medicine Expert Ken Herrmann, MD, MBA | Board appointment underscores the company's continued advancement of its alpha radiopharmaceutical platform capabilities BOSTON, June 13, 2024 /PRNewswire/ -- Aktis Oncology, a clinical-stage biotechnology company discovering and developing... |
| 23.05.2024 | Aktis Oncology forms major drug-discovery collaboration with Eli Lilly | Two bioscience companies with operations in Durham are teaming up to discover new cancer therapies. The collaboration between Boston-based Aktis Oncology and Indianapolis-based Eli Lilly and Company is aimed at developing radiopharmaceutica... |
| 21.05.2024 | Aktis Oncology enters into Strategic Collaboration with Lily to Discover and Develop Novel Anticancer Radiopharmaceuticals | - |
| 21.05.2024 | AKTIS ONCOLOGY ENTERS INTO STRATEGIC COLLABORATION WITH LILLY TO DISCOVER AND DEVELOP NOVEL ANTICANCER RADIOPHARMACEUTICALS | Collaboration to utilize Aktis Oncology's proprietary miniprotein discovery platform to generate novel tumor-targeting radiopharmaceuticals Aktis responsible for program discovery through initial human imaging studies; Lilly responsible for... |
| 26.08.2022 | Aktis Oncology Raises $84M in Series A Extension Funding | Aktis Oncology, a Cambridge, MA-based biotechnology company focused on advancing alpha radiopharmaceuticals to treat solid cancers, raised $84M in Series A funding. The round was led by Cowen Healthcare Investments, MRL Ventures Fund, Arrow... |
| 25.08.2022 | Aktis Oncology Inks $84M Series A Extension | CAMBRIDGE, MA, Aktis Oncology today announced it has raised a Series A Extension financing of $84 million. >> Click here for more funding data on Aktis Oncology >> To export Aktis Oncology funding data to PDF and Excel, clic... |
Show more